The purpose of this study is to evaluate the systemic exposure of BDP, its metabolite beclomethasone 17-monopropionate (B17MP) and formoterol after inhalation of BDP/Formoterol 100/6 µg pMDI combination (CHF1535) using the standard actuator and charcoal block technique or using a Spacer (AeroChamber Plus, Trudell) in comparison with inhalation using the standard actuator
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
13
CROSS Research SA
Arzo, Via F.A. Giorgioli, 14, Switzerland
Systemic exposure and lung bioavailability of BDP, B17MP and formoterol.
Time frame: from pre-dose until 12 h post-dose
General tolerability and safety of the test product.
Time frame: from pre-dose until 12 h post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.